NCT04875962View on ClinicalTrials.gov

A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

May 6, 2019

Primary Completion Date

February 19, 2020

Study Completion Date

February 19, 2020

Conditions
Parkinson's Disease
Interventions
DRUG

UCB0599

Participants will receive an assigned dosage regimen of UCB0599 during the Treatment Period.

DRUG

Placebo

Participants will receive an assigned dosage regimen of Placebo during the Treatment Period to maintain the blinding.

Trial Locations (6)

27612

Up0077 104, Raleigh

30331

Up0077 107, Atlanta

32720

Up0077 105, DeLand

33154

Up0077 103, Bay Harbor Islands

48334

Up0077 101, Farmington Hills

90806

Up0077 102, Long Beach

All Listed Sponsors
lead

UCB Biopharma S.P.R.L.

INDUSTRY

NCT04875962 - A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD) | Biotech Hunter | Biotech Hunter